ArticleCancer management and research2018
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Cytochrome P450 17 (CYP17), CYP2C19*2, CYP2C19*3 Gene Polymorphisms and Gastrointestinal Cancer Risk in Rural Maharashtra: A Hospital based Case-Control Study.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- The Effect ofPharmacogenomics and personalized medicine · 2022Article
- Impact of genetic variants in IL-2RA and IL-2RB on breast cancer risk in Chinese Han women.Biochemical genetics · 2021Article
- The association of CASC16 variants with breast Cancer risk in a northwest Chinese female population.Molecular medicine (Cambridge, Mass.) · 2020Article
- Association study between the polymorphisms of angiogenesis-related genes and cervical cancer susceptibility in Chinese Uygur population.Molecular genetics & genomic medicine · 2019Article
- Assessment of the association between ACYP2 and laryngeal squamous cell carcinoma risk in Chinese males.Molecular genetics & genomic medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCYP17 is the second most important enzyme in estradiol synthesis. Epidemiological studies have shown the associations between PATIENTS AND
methodsThis case-control study included 560 BC patients and 583 age-matched healthy controls from Northwest China. Two polymorphisms (rs743572 and rs2486758) of
resultsCompared with the wild genotype of rs743572, we found a significantly reduced risk of BC associated with the variant genotypes (heterozygote model: OR=0.69, 95% CI=0.53-0.89; homozygote model: OR=0.68, 95% CI=0.49-0.95; dominant model: OR=0.69, 95% CI=0.54-0.87; overdominant model: OR=0.78, 95% CI=0.62-0.98; allele model: OR=0.79, 95% CI=0.66-0.93). For rs2486758 polymorphism, we did not find any difference in any of the genetic models. Further stratification analysis by clinical characteristics showed rs743572 was associated with estrogen receptor status (heterozygote model: OR=2.13, 95% CI=1.47-3.08; homozygote model: OR=3.29, 95% CI=1.94-5.58; dominant model: OR=2.39, 95% CI=1.69-3.37) and progesterone receptor status (homozygote model: OR=3.17, 95% CI=1.82-5.55), but there was no association between rs2486758 and clinical characteristics of BC. Haplotype analysis showed that G
conclusionOur results suggest that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.